Michael Davis becomes Cyanotech chairman
Hawaiian microalgae technology company looks forward to continuing support of its major shareholder
Davis was vice-chairman of the board and has been a director of Cyanotech since March 2003.
‘Michael has been a key influence in helping Cyanotech sharpen its business model and market focus in recent years,’ said Brent Bailey, president and ceo. ‘We look forward to his continuing support and leadership as chairman of the board.’
Cyanotech Corporation, a microalgae technology specialist, produces BioAstin Natural Astaxanthin and Hawaiian Spirulina Pacifica, which are natural, functional nutrients.
You may also like
Ingredients
![Resonant clinical solutions and Haier Biomedical introduce an innovative Benchtop centrifuge with a nantural refrigerant]()
Resonant clinical solutions and Haier Biomedical introduce an innovative Benchtop centrifuge with a nantural refrigerant
Resonant Clinical Solutions – a global clinical solutions partner serving life sciences organisations across the clinical supply chain and sample lifecycle – and Haier Biomedical – a trusted leader in reliable and sustainable laboratory equipment – have launched an innovative benchtop centrifuge using a natural refrigerant
Ingredients
![dsm-firmenich launches Biond pharmaceutical-grade vitamin portfolio for cell culture and biologics manufacturing]()
dsm-firmenich launches Biond pharmaceutical-grade vitamin portfolio for cell culture and biologics manufacturing
The range targets critical metabolic pathways supporting cell growth, viability and protein expression — available globally through Brenntag's BYPHAR distribution network ahead of its CPHI Milan debut
Manufacturing
![CARBOGEN AMCIS announces successful first FDA pre-approval inspection at its Vionnaz site]()
CARBOGEN AMCIS announces successful first FDA pre-approval inspection at its Vionnaz site
CARBOGEN AMCIS part of the Dishman Carbogen Amcis Group, a leading pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, is pleased to announce the successful completion of the first U.S. Food and Drug Administration (FDA) Pre-Approval Inspection (PAI) at its Vionnaz facility in Switzerland. The inspection concluded without the issuance of a Form 483
